A Study of rhuMAb IFNalpha in Adults With Systemic Lupus Erythematosus

Inclusion Criteria: * For patients with reproductive potential (males and females), use of a reliable means of contraception (e.g., hormonal contraceptive, patch, vaginal ring, intrauterine device, physical barrier) throughout their participation in the study * Diagnosis of SLE according to current American College of Rheumatology (ACR) criteria * Disease duration of ≥ 1 year (after first diagnosis by a physician) * Current immunity to measles, mumps, rubella, and varicella, as evidenced by positive IgG titers at the time of screening * Current vaccination against influenza unless contraindicated in the investigator's judgment * Normal Pap smear within the applicable time interval recommended by current American Cancer Society guidelines Exclusion Criteria: * Presence of active lupus nephritis * Presence of active central nervous system (CNS) disease requiring treatment with high-dose corticosteroids or immunosuppressive agents * Presence of active vasculitis requiring treatment * History of arterial or venous thromboses within 12 months of screening * Moderate to severe anemia, thrombocytopenia, or neutropenia * Any manifestation likely to require, in the investigator's judgment, treatment with high-dose corticosteroids or the addition of an immunosuppressive regimen during the course of the trial * Pregnancy or lactation * Lack of peripheral venous access * History of alcohol or substance abuse within 6 months of screening * History of severe allergic or anaphylactic reactions to antibodies or fusion proteins * Evidence of significant uncontrolled concomitant diseases * Significant laboratory or electrocardiogram (ECG) abnormalities * Evidence of any clinically significant abnormality on a chest X-ray * Severly impaired renal function * Impaired hepatic function * Poorly controlled diabetes * Conditions other than SLE that could require treatment with corticosteroids * History of malignancy except completely excised basal cell carcinoma * Congenital immune deficiency * Positive tests for antibodies to HIV, hepatitis B (HBS antigen, anti-HBC) or C * Positive IgM antibody titers in the presence of negative IgG titers to Epstein-Barr virus (EBV) or cytomegalovirus (CMV) * Frequent recurrence of herpes lesions * Episode of shingles within one year of screening * Positive screening test for latent mycobacterium tuberculosis infection * History of severe systemic bacterial, fungal, viral, or parasitic infections within the year prior to screening * Any current or recent signs or symptoms of infection * Received antibiotics orally (PO) during the 30 days prior to screening or IV antibiotics during the 60 days prior to screening * Received a live vaccine within the 30 days prior to screening * Has been hospitalized within the 30 days prior to screening * Received \> 20 mg/day prednisone for \> 3 days during the 30 days prior to screening * Received azathioprine, methotrexate, mycophenolate mofetil, cyclosporine, tacrolimus, sirolimus, pulse dose corticosteroids, intravenous immunoglobulin (IVIG), or transfusions within 6 months prior to screening * Received cyclophosphamide within 2 years prior to screening * Received a monoclonal antibody during the 12 months prior to screening * Previously received an investigational treatment directed against interferon alpha * Received B-cell depleting therapy (e.g., anti-CD20, anti-CD22) * Received investigational treatment during the 30 days prior to screening